v


Zhengzhou First Affiliated Hospital Successfully Completes 12 SHURUI® Single-Port Surgical Robotic Esophageal Cancer Surgeries — Ushering a New Era in Minimally Invasive Esophageal Cancer Treatment

 

Recently, the thoracic surgery team led by Directors Xiangnan Li and Jia Zhao at Zhengzhou University First Affiliated Hospital achieved a major milestone by performing 12 esophageal cancer radical resections using the SHURUI® single-port surgical robot. This marks a significant breakthrough in minimally invasive esophageal cancer treatment in China.

 

Unlike traditional multi-port robotic systems such as Da Vinci SP, which require multiple incisions and have limited operating range, the SHURUI® system enables a single 3cm intercostal incision with a flexible snake-arm reach of 22cm, covering the entire esophagus and mediastinum without frequent arm repositioning.

 

The innovative sheath design avoids tissue damage caused by instrument-rib friction seen in rigid systems. Average surgery time was approximately 4 hours, nearly 15% faster than comparable procedures using Da Vinci SP.

 

This successful series validates the SHURUI® system’s clinical efficacy and safety, establishing a pioneering “China solution” for esophageal cancer minimally invasive surgery and paving the way for future clinical guidelines and wider adoption.

 

Important Notes

The SHURUI Single-port Endoscopic Surgical System (SR-ENS-600), developed and produced by Beijing Surgerii Robotics Company Limited, has obtained the CE marking for urologic laparoscopic surgical procedures, gynecologic laparoscopic surgical procedures, general laparoscopic surgical procedures, and thoracoscopic surgical procedures. It is intended for use by trained surgeons in an operating room environment in accordance with the representative, specific procedures set forth in the User Manual.

Safety and Performance Information

Beijing Surgerii Robotics Co., Ltd. owns Surgerii®, SHURUI®, and other trademarks and may not be used without permission.